Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small

Dec 17, 2024 · 1. The large language model, ChatGPT-4, answered 85.0% of examination-style multiple-choice questions on medical oncology correctly, a performance superior to all other large language models and comparable with medical oncology trainees. 2. Approximately 80% of incorrect answers were rated by clinicians as having a …

Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications

Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.

Oct 3, 2024 · 1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed against TL1A, more effectively induced clinical remission compared with placebo. 2. Compared with placebo, the tulisokibart group consistently showed benefits in clinical response, endoscopic improvement, histologic improvement, symptomatic ...

Sep 23, 2024 · 1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the 400-mg group. 2. Adverse events of any cause were reported in 67%-74% in the ponsegromab group vs 80% in

Nov 21, 2024 · 1. In this randomized controlled trial, among patients with a history of myocardial infarction (MI), interruption of long-term beta-blocker therapy was not found to be noninferior to beta-blocker continuation in preventing death, MI, stroke, and hospitalization for cardiovascular reasons. 2. Interruption of long-term beta-blocker therapy did not improve patient-reported quality of …

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting.

Dec 16, 2024 · 1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR 0.57 (significant) and 5.6 months in the imlunestrant group vs 5.5 months in the standard-therapy group with HR 0.87 (non-significant). 2. With regards to safety, adverse …

Oct 28, 2024 · 1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration during upper gastrointestinal endoscopy discontinuation compared to the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. 2. The use of GLP-1 receptor agonists among adults with T2DM was associated